# Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme

**Source**: Hospital Pharmacy Journal 2015;50(8):672-677  
**Authors**: Matthew R. Rutledge, BSc, BCOP; J. Aubrey Waddell, PharmD, FAPhA, BCOP; Dominic A. Solimando, Jr, MA, FAPhA, FASHP, BCOP  
**DOI**: 10.1310/hpj5008-672  
**Publication**: Thomas Land Publishers, Inc.  
**Extracted**: September 2024

---

## REGIMEN OVERVIEW

### Regimen Name
**Bevacizumab and Temozolomide Plus Radiation**

### Origin of Name
Named for the 3 components comprising the regimen: bevacizumab, temozolomide, and radiation therapy.

### Clinical Context
This regimen administers bevacizumab and temozolomide concurrently with radiotherapy in the initial treatment phase, followed by bevacizumab and temozolomide alone in the adjuvant/maintenance phase where temozolomide dose increases dramatically and changes from daily dosing to a 5-day pulse.

---

## INDICATIONS

### Primary Indication
- **Newly diagnosed glioblastoma multiforme (GBM)**: Initial therapy combining all three modalities
- **Evidence basis**: Multiple Phase II clinical trials (2011-2015)

### Background Evidence
- **Concomitant TMZ + RT**: Recommended for adjuvant treatment of newly diagnosed GBM
- **Bevacizumab monotherapy**: Recommended for recurrent disease
- **Combination approach**: Investigational for newly diagnosed GBM based on trials reviewed

### Referenced Clinical Studies
1. **Gilbert MR et al** (NEJM 2014) - RTOG 0825 randomized trial
2. **Chinot OL et al** (NEJM 2014) - AVAglio trial  
3. **Narayana A et al** (J Neurosurg 2012) - Phase II trial
4. **Ney DE et al** (J Neurooncol 2015) - Hypofractionated RT trial
5. **Omuro A et al** (Clin Cancer Res 2014) - Stereotactic RT trial
6. **Lai A et al** (J Clin Oncol 2011) - Phase II combination trial

---

## TREATMENT PROTOCOL

### Phase I: Concomitant Treatment (6 weeks)

| Drug | Dose | Route | Schedule | Total Dose/Cycle |
|------|------|-------|----------|-------------------|
| **Bevacizumab** | 10 mg/kg | IV | Days 1, 15 | 20 mg/kg |
| **Temozolomide** | 75 mg/m² | PO | Daily | Maximum 49 doses (3,675 mg/m²) |
| **Radiation** | 2 Gy/day | External beam | 5 days/week × 6 weeks | 60 Gy total |

**Cycle**: Single 6-week course of therapy

#### Radiation Therapy Variations
1. **Standard fractionation**: 1.8 Gy per fraction to 59.4 Gy total
2. **Shortened course**: 42 days temozolomide duration
3. **Hypofractionated**: 6 Gy per fraction × 10 treatments over 2 weeks
4. **Stereotactic**: 6-Gy treatments × 6 over 2 weeks with 2-week TMZ

### Phase II: Maintenance Treatment

| Drug | Dose | Route | Schedule | Total Dose/Cycle |
|------|------|-------|----------|-------------------|
| **Bevacizumab** | 10 mg/kg | IV | Days 1, 15 | 20 mg/kg |
| **Temozolomide** | 150-200 mg/m² | PO | Days 1-5 | 750-1,000 mg/m² |

**Cycle length**: 28 days  
**Standard duration**: 6 cycles

#### Maintenance Protocol Variations
1. **Dose escalation**: 150 mg/m² × 5 days Cycle 1, then 200 mg/m² for subsequent cycles
2. **Extended treatment**: Option to continue to 12 cycles total
3. **Alternative scheduling**: TMZ days 1-7, bevacizumab days 8, 22
4. **Physician discretion**: Extension beyond 6 cycles
5. **Maximum duration**: Up to 24 cycles in some protocols

---

## DRUG PREPARATION AND ADMINISTRATION

### Hazardous Drug Handling
**Follow institutional policies** for preparation of hazardous medications when preparing bevacizumab and dispensing temozolomide.

### Bevacizumab Preparation
1. **Concentration**: Use 25 mg/mL injection
2. **Dilution**: Dilute dose in 100 mL 0.9% sodium chloride injection

### Bevacizumab Administration
1. **Surgery restriction**: Do not administer within 28 days of major surgery or until surgical wound fully healed
2. **Infusion schedule**:
   - **First dose**: 90 minutes
   - **Second dose**: 60 minutes (if first dose tolerated)
   - **Subsequent doses**: 30 minutes (if second dose tolerated)

### Temozolomide Preparation
1. **Available strengths**: 5, 20, 100, 140, 180, 250 mg capsules
2. **Route**: Oral (PO) only
3. **Dose combinations**: Prescribed dose may require multiple capsule strengths
4. **Dose rounding**: Round to nearest 5 mg
5. **Capsule integrity**: Manufacturer recommends capsules not be opened
6. **Alternative formulation**: Extemporaneous oral suspension available (limited stability)

### Temozolomide Administration
1. **Frequency**: Once daily
2. **Timing**: Empty stomach with glass of water to minimize nausea
3. **Food interaction**: Food increases gastric irritation and affects absorption unpredictably
4. **Dose accuracy**: Multiple of 5 mg
5. **Patient education**: Ensure understanding of multiple capsule strengths per dose
6. **Dispensing strategy**: Consider separate daily containers to prevent dosing errors

---

## SUPPORTIVE CARE PROTOCOLS

### Antiemetic Prophylaxis

#### Concomitant Phase (Low Risk)
- **Emesis risk**: <10% predicted
- **Grade 3+ nausea/vomiting**: 2-5% reported in studies
- **Prophylaxis**: Generally not required for most patients
- **Radiation-induced**: Low risk, may warrant prophylaxis

**If needed, use one of:**
1. Ondansetron 8-16 mg PO 30 minutes before radiation
2. Granisetron 1-2 mg PO 30 minutes before radiation  
3. Dolasetron 100 mg PO 30 minutes before radiation

#### Maintenance Phase (Moderate-High Risk)
- **Emesis risk**: 30-90% predicted (higher TMZ dose)
- **Grade 3+ reported**: 5% in studies with 5-HT3 antagonists
- **Prophylaxis**: Recommended with serotonin antagonist

**Recommended regimens (30 minutes before TMZ):**
1. Ondansetron 16-24 mg PO once daily
2. Granisetron 1-2 mg PO once daily
3. Dolasetron 100 mg PO once daily

#### Breakthrough Nausea Treatment
**Options include:**
1. Metoclopramide 10-40 mg PO q4-6h PRN ± diphenhydramine 25-50 mg q6h PRN
2. Prochlorperazine 10 mg PO q4-6h PRN ± diphenhydramine 25-50 mg q6h PRN  
3. Prochlorperazine 25 mg rectally q12h PRN ± diphenhydramine 25-50 mg q4-6h PRN
4. Promethazine 25-50 mg PO q4-6h PRN ± diphenhydramine 25-50 mg q4-6h PRN

### Hematopoietic Growth Factor Guidelines
- **CSF indication**: >20% febrile neutropenia risk
- **Consider CSFs**: 10-20% febrile neutropenia risk  
- **Not recommended**: <10% febrile neutropenia risk
- **Trial results**: No febrile neutropenia reported
- **Severe neutropenia**: 7-33% (Grade 3-4)
- **Recommendation**: Prophylactic CSFs not recommended
- **Exception**: Consider if prior febrile or Grade 4 neutropenia

### Pneumocystis Prophylaxis
- **Indication**: ALL patients receiving concomitant TMZ + radiotherapy
- **Duration**: Continue until lymphocytopenia recovery
- **Study variations**:
  - Gilbert et al: CD4 <200/mm³
  - Ney et al: Physician discretion
  - Omuro et al: All patients

---

## COMPREHENSIVE TOXICITY PROFILE

### Grading System
**National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)**
- **Grade 1-2**: Generally no dose adjustments
- **Grade 3-4**: Consider dose reductions or therapy changes

### Cardiovascular Toxicities
- **Hemorrhage (Grade 3)**: 1%
- **Cerebral hemorrhage**: Grade 3 (1%), Grade 4 (1%)
- **Congestive heart failure (Grade 3-4)**: 0.44%
- **Stroke (Grade 3-4)**: 3%
- **Cerebrovascular ischemia (Grade 4)**: 9%
- **Hypertension**: Grade 3 (6-11%), Grade 3-4 (11%)
- **Thromboembolic events**: Grade 3 (4-10%), Grade 4 (2-9%), Grade 3-4 (3-8%)

### Gastrointestinal Toxicities  
- **Nausea/vomiting**: Grade 3 (2-5%), Grade 3-4 (3%)
- **Diarrhea (Grade 3)**: 1%
- **GI perforation**: Grade 3 (1%), Grade 4 (0.4-1%)
- **Abscess and fistula**: 0.44%
- **GI bleeding (Grade 3)**: 3%

### Hematologic Toxicities
- **Anemia**: Grade 3 (2%), Grade 4 (1%)
- **Leukopenia**: Grade 3 (11%), Grade 4 (3%)
- **Lymphopenia**: Grade 3 (18%), Grade 4 (5%)
- **Neutropenia**: Grade 3 (10-33%), Grade 4 (7-10%)
- **Thrombocytopenia**: Grade 3 (6-10%), Grade 4 (4-17%), Grade 3-4 (15%)

### Hepatic Toxicities
- **ALT elevations**: Grade 3 (3%), Grade 4 (1%)
- **AST elevations (Grade 3)**: 3%

### Neurologic Toxicities
- **Fatigue/asthenia**: Grade 3 (2-20%), Grade 4 (1%), Grade 3-4 (7-13%)
- **Dizziness/syncope (Grade 3)**: 7%
- **Seizure (Grade 3)**: 9%

### Renal Toxicities
- **Elevated creatinine (Grade 3)**: 1%
- **Proteinuria**: Grade 3 (9%), Grade 3-4 (5%), Grade 4 (3%)
- **Hyponatremia**: Grade 3 (10%), Grade 4 (1%)

### Other Significant Toxicities
- **Wound complications**: Grade 3 (2%), Grade 4 (0.4%), Grade 3-4 (3-7%)
- **Infection (Grade 3)**: 13%
- **Hyperglycemia (Grade 3)**: 10%
- **Ocular problems**: Grade 3 (1%), Grade 4 (1%)

### Treatment-Related Deaths (Critical Safety Data)
- **Thromboembolic disease**: 0.4%
- **Hemorrhage**: 0.2-0.4%
- **Cranial wound dehiscence/infection**: 2-7%
- **Sepsis**: 3%
- **Sudden death from presumed seizure**: 3%
- **Respiratory/lung disorders**: 0.2%
- **Cardiac disorders**: 1%
- **GI perforation**: 0.2%
- **Brain edema**: 0.2%
- **Hepatotoxicity**: 0.2%
- **Unspecified**: 3%

---

## PRETREATMENT REQUIREMENTS

### Baseline Laboratory Assessment
1. **AST/ALT**
2. **Total bilirubin**
3. **Serum creatinine**
4. **Complete blood count with differential**
5. **Blood pressure**
6. **Urine dipstick analysis**

### Prior to Each Treatment
1. **CBC with differential**
2. **Blood pressure**
3. **Urine dipstick analysis**

### Required Pretreatment Values
**From clinical trials:**
1. **ANC**: ≥1,500 cells/mcL
2. **Platelets**: ≥100,000 cells/mcL
3. **Hemoglobin**: ≥9 g/dL
4. **Creatinine**: ≤1.5 mg/dL
5. **AST**: ≤1.5 × ULN
6. **Bilirubin**: ≤1.5 × ULN
7. **Proteinuria**: Urine protein:creatinine ratio ≤1.5

**Clinical practice standards:**
- **ANC**: ≥1,000 cells/mcL (acceptable)
- **Platelets**: ≥75,000 cells/mcL (acceptable)

### Surgery Requirements
- **Minimum 4 weeks** after surgical debulking before starting bevacizumab
- **Blood pressure monitoring**: Every 2-3 weeks during treatment (manufacturer recommendation)

---

## DOSAGE MODIFICATIONS

### Renal/Hepatic Dysfunction
**No specific dose modifications** established in reviewed trials for renal or hepatic dysfunction.

### Bevacizumab-Specific Modifications

#### Hypertension Management
- **Mild-moderate**: Treat with antihypertensive therapy
- **Uncontrolled**: Temporarily suspend bevacizumab
- **Hypertensive crisis/encephalopathy**: Discontinue bevacizumab permanently
- **Monitoring**: Continue BP monitoring after discontinuation

#### Proteinuria Management
- **Monitoring**: Urine dipstick analysis recommended
- **2+ dipstick**: Obtain 24-hour urine collection
- **Grade >2 without nephrotic syndrome**: Hold bevacizumab until resolution
- **≥2 g/24 hours**: Hold bevacizumab until <2 g/24 hours
- **Nephrotic syndrome**: Discontinue bevacizumab

### Temozolomide Modifications
#### Study-Specific Approaches
- **Ney et al**: 25% dose reduction for Grade 3-4 hematologic toxicity
- **Lai et al**: Follow manufacturer's package insert for hematologic toxicity
- **Narayana et al**: Grade 4 toxicity or TMZ rash = contraindication to further therapy

---

## CLINICAL STUDY REFERENCES

### Primary Evidence Base
1. **Gilbert MR, Dignam JJ, Armstrong TS, et al**. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370(8):699-708.

2. **Chinot OL, Wick W, Mason W, et al**. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370(8):709-722.

3. **Lai A, Tran A, Nghiemphu PL, et al**. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. *J Clin Oncol*. 2011;29(2):142-148.

### Supporting Studies
4. **Narayana A, Gruber D, Kunnakkat S, et al**. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. *J Neurosurg*. 2012;116(2):341-345.

5. **Ney DE, Carlson JA, Damek DM, et al**. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. *J Neurooncol*. 2015;122(1):133-143.

6. **Omuro A, Beal K, Gutin P, et al**. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. *Clin Cancer Res*. 2014;20(19):5023-5031.

---

## CLINICAL IMPLICATIONS

### Historical Context
This protocol represents the **post-Phase III trial era** (2014-2015) when bevacizumab was investigated intensively for newly diagnosed GBM following its FDA approval for recurrent disease.

### Key Clinical Insights
1. **Failed primary endpoints**: Large Phase III trials (RTOG 0825, AVAglio) did not show OS benefit
2. **PFS benefit demonstrated**: Both major trials showed progression-free survival improvement
3. **Quality of life concerns**: Some evidence of neurocognitive decline with bevacizumab
4. **Safety profile**: Well-characterized with specific incidence rates for major toxicities
5. **Current status**: Not FDA-approved for newly diagnosed GBM due to lack of OS benefit

### Practice Considerations
1. **Off-label use**: This combination requires careful patient selection
2. **Informed consent**: Discuss lack of proven OS benefit vs potential PFS improvement
3. **Safety monitoring**: Enhanced surveillance for bevacizumab-specific toxicities
4. **Supportive care**: Comprehensive antiemetic and PCP prophylaxis protocols essential
5. **Alternative approaches**: Consider participation in clinical trials

---

*This comprehensive protocol represents expert oncology pharmacy guidance for the investigational combination of bevacizumab, temozolomide, and radiation therapy for newly diagnosed glioblastoma multiforme, based on multiple Phase II clinical trials conducted 2011-2015.*